Introduction
============

Colorectal cancer is the third-most commonly diagnosed cancer in males and the second-most common in female [@B1]. Each year, more than 1.2 million new cases of colorectal cancer are diagnosed worldwide [@B2]. Previously, colorectal cancer has its highest incidence in Western Europe and North America, but recently, the mortality and morbidity of colorectal cancer rapidly grows in the Chinese population in Northwest China region. According to the latest Cancer Statistics of China, colorectal cancer is the fifth newly diagnosed cancer among men, and the fourth among women in China [@B3]. Among those colorectal cancer patients, rectal cancer represents 40 percent of colorectal cancers. While curative surgery is the only option for long term survival, rectal cancer spreads more frequently to the thoracic organs, bone and nervous system and approximately 20% of rectal cancer patients lose opportunity for radical surgery on account of metastases [@B4], [@B5].

Although prognostic factors for rectal cancer have conducted intensive studies, including in the field of molecular biology, but for the prognosis of rectal cancer can be different despite similar stages and grades [@B6]. A better understanding of an ideal biomarker with readily available, inexpensive and reproducible of rectal cancer could improve the prognosis of patients and provide appropriate therapy strategies. Recently, the correlation between the ABO blood type and other malignancies, such as breast cancer, pancreatic cancer, lung cancer, esophageal squamous cell carcinoma, colon cancer, nasopharyngeal carcinoma, and obstetric cancers, has been continuously reported [@B7]-[@B14].

Previously Hamed et al. [@B15] enrolled 1025 colorectal cancer patients in two large prospective cohorts and observed the relationship between ABO blood group and risk of colorectal cancer, their results showed that the ABO blood group didn\'t have any association with risk of colorectal cancer. Well-known, many genetic and environmental risk factors were defined for cancer, including smoking, obesity, a higher-fat diet, rectal polyp and a family history. However, up to now, studies of the impact of ABO blood group on the survival of the Chinese population in Northwest China region with rectal cancer remained uncertain. Therefore, the aim of this retrospective analysis was to analyze the relationship between ABO blood type and the survival of rectal cancer patients in a Chinese population in Northwest China region as there is an interpopulation variation for this condition.

Material and Methods
====================

Patient selection
-----------------

The retrospective study included 1613 patients who were diagnosed with rectal adenocarcinoma and treated surgically between June, 2011 and December, 2016 at Division of Gastrointestinal Surgery, First Affiliated Hospital of Air Force Military Medical University. Enrolled patients were histologically confirmed and without distant metastasis. Patients with one of the following features, (stage IV) rectal cancer, with more than one primary cancer, with R1 or R2 resection, or death from postoperative complications, were excluded from our study. Other patients with missing data were also excluded. Patients were considered eligible only when the following data were available. Tumor differentiation grades were defined according to the World Health Organization criteria. Cancer staging was based on the American Joint Committee on Cancer Staging system (AJCC, 2002; Greene, American Joint Committee on Cancer, American Cancer Society, 2002). The study was approved by the ethics committee of First Affiliated Hospital of Air Force Military Medical University. All patients provided written consent for storage of their information in the hospital database, and for the research use of the information.

Follow-up and outcome
---------------------

Each patient was followed up periodically until death or April 2017(every 3 mouth for the first 2 y, and every 6 mouth up to the fifth year) after surgery. The follow-up cycles varied from 3-6mo, with a median of 69.6 months. The follow-up visits consisted of a physical examination and laboratory studies at least every 6 months or when clinically indicated. The endpoint of the study was overall survival (OS). OS was calculated as the period from the date of diagnosis to the date of death from any cause or the date of last follow-up. Survival status was verified again using the best available methods, including checking clinical attendance records and direct telecommunication with the patients or their families.

A validation cohort
-------------------

An independent cohort included 505 rectal adenocarcinoma patients who were diagnosed and treated surgically between December, 2012 and December, 2015 at Division of Gastrointestinal Surgery, Second Affiliated Hospital of Air Force Military Medical University, were used for confirm the above results. The admission and exclusion condition of the enrolled patients were the same as before. All patients provided written consent for storage of their information in the hospital database, and for the research use of the information. Each patient was followed up periodically until death or April 2017 (every 3 mouth for the first 2 y, and every 6 mouth up to the fifth year) after surgery. The follow-up cycles varied from 3-6mo, with a median of 59.6 months. The follow-up visits consisted of a physical examination and laboratory studies at least every 6 months or when clinically indicated. The endpoint of the study was overall survival (OS). OS was calculated as the period from the date of diagnosis to the date of death from any cause or the date of last follow-up. Survival status was verified again using the best available methods, including checking clinical attendance records and direct telecommunication with the patients or their families.

Statistical analysis
--------------------

Chi-square test was used to compare categorical variables. ANOVA test was used to compare continuous variable, if they have no homogeneity of variance, then Kruskal Wallis Test will be used. The survival rates were evaluated by Kaplane-Meier survival analysis, and their significance was calculated by the log-rank test. Univariate and multivariate Cox regression analyses were performed. Multivariable analyses were performed for factors which were significantly associated with OS in univariate analyses. All the statistical analyses were conducted using IBM SPSS 20.0 software. A P value \<0.05 was considered to be statistically significant.

Results
=======

ABO blood group and clinicopathologic characteristics of the rectal cancer patients
-----------------------------------------------------------------------------------

A total of 1613 eligible patients with rectal cancer were analyzed at the gastrointestinal surgery in First Affiliated Hospital of Air Force Military Medical University from June, 2011 to December, 2016. Clinicopathologic characteristics of all subjects stratified by ABO blood group were displayed in Table [1](#T1){ref-type="table"}. Based on the seventh edition of the TNM-UICC/AJCC classification system, the numbers of patients with stage I, II, and III disease were 439 (27.2%), 427 (26.5%), and 747(46.3%), respectively. The median age of the patients was 59 years (range, 19-86 years). Among the 1613 subjects, 411 (25.5%) were blood group A, 502 (31.1%) were blood group B, 545(33.8%) were blood group O, and the remaining 155 (9.6%) were blood group AB. No significant difference was found regarding gender, age, tumor size, tumor location, BMI, degree of differentiation, lymphatic/vascular invasion, perineural invasion, N stage, smoking history, drinking history, CEA level, CA199 level and CA125 level.

Association between the clinical prognosis of rectal cancer patients and ABO blood groups
-----------------------------------------------------------------------------------------

The median follow-up period of the 1613 rectal cancer patients was 69.6 months with 1427 (88.5%) alive and 186 (11.5%) dead from cancer-related diseases at the final clinical follow-up. The 5-year overall survival rates for rectal adenocarcinoma patients with the A, B, O and AB blood types were 84.9%, 89.2%, 91.2% and 85.8%, respectively. The ABO blood groups were closely associated with OS according to the Kaplane-Meier analysis (P=0.007) Figure [1](#F1){ref-type="fig"}A. OS was longer in rectal cancer patients with the group B (median, 70.8mo, 95% CI, 67.9-73.6 months) than in those with the group A (median, 58.4mo, 95% CI, 55.4-61.3 months), group O (median, 64.3mo, 95% CI, 62.2-66.5months), and group AB (median, 59.7mo, 95% CI, 55.2-64.2 months) (P = 0.007). Meanwhile, we found that the blood types B and O seemed to have a higher survival than blood types A and AB, therefore, we divided the whole group of patients into two subgroups. The subgroup analysis indicated that patients of blood group B and O had a longer OS compared to those of blood group A and AB (71.6 months vs. 58.8 months, P = 0.001) as shown in Figure [1](#F1){ref-type="fig"}B.

Then the relationship between ABO blood type and survival based on patients\' clinicopathologic characteristics were examined. These analysis showed that ABO blood group could distinguish OS when stratified by gender (Female, P=0.014), age(\<60, P=0.028), smoking history (no smoking, P=0.017) ,drinking history (no drinking, P=0.046), CEA (normal, P=0.007), CA199 (elevated, P=0.013), CA-125 (normal, P=0.004), tumor location (tumor height \<6 cm, P=0.006),tumor size (≥3.4cm, P=0.009), pathology (well differentiated, P\<0.001; poorly differentiated, P=0.014), perineural invasion (yes, P=0.023), vascular invasion (no, P=0.004), pT status (T1, P=0.026; T3, P=0.003), pN status (no, P=0.001).

To determine whether ABO blood type could serve as an independent prognostic factor, we examined OS using the Cox proportional hazards model. Univariate analysis was used to evaluated the influence of the patients\' gender, age, body mass index(BMI),tumor location, pathology differentiation, lymphatic/vascular invasion, perineural invasion, T status, N status, TNM stage, smoking history, drinking history, ABO blood type, tumor size, serum CEA , CA199 and CA125 level on OS (Table [2](#T2){ref-type="table"}). Our results showed that the poorly differentiated histology (P\<0.001), lower BMI (P=0.007), lymphatic/vascular invasion (P\<0.001), advanced pT stages (P \<0.001), advanced pN stages (P\<0.001), advanced tumor stages (P \<0.001), ABO blood type (P=0.010) ,lower tumor height (P\<0.001), bigger tumor size (P\<0.001), serum CEA elevation (P = 0.011) , serum CA-199 elevation (P\<0.001) and serum CA-125 elevation (P\<0.001) were all significantly associated with shorter survival. Furthermore, the significant parameters in univariate analysis were also performed by multivariate analyses. The results revealed that lower BMI (P=0.031), lower tumor height (P=0.021), poorly differentiated histology (P=0.005), lymphatic/vascular invasion (P=0.017), advanced pN stages (P=0.029), ABO blood type (P=0.010), serum CA-199 elevation (P=0.022) and serum CA-125 elevation (P\<0.001) were independent, significant predictors for OS (Table [2](#T2){ref-type="table"}).

Validation in an independent cohort
-----------------------------------

In order to validate our results, we used an independent cohort from another hospital for further confirm and the clinicopathologic characteristics of all subjects stratified by ABO blood group were displayed in Table [3](#T3){ref-type="table"}. There were 505 enrolled rectal cancer patients, 287 (56.8%) male and 218 (43.2%) female, aged from 23-88 y (the median age was 69 y). Based on the seventh edition of the TNM-UICC/AJCC classification system, the numbers of patients with stage I, II, and III disease were 141 (27.9%), 124 (24.6%), and 240 (47.5%), respectively. The ABO blood groups were distributed as 140 patients with the blood group A, 142 patients with the blood group B, and 161 patients with the blood group O, and 62 patients with the blood group AB. Our results showed that the ABO blood groups were closely associated with OS according to the Kaplane-Meier analysis (P=0.003) Figure [2](#F2){ref-type="fig"}A. OS was longer in rectal cancer patients with the group O (median, 63.8mo, 95% CI, 59.1-68.7 months) than in those with the group B (median, 63.3mo, 95% CI, 58.9-67.7 months), group A (median, 54.7mo, 95% CI, 48.9-60.5months), and group AB (median, 54.3mo, 95% CI, 46.3-62.3 months) as shown in Figure [2](#F2){ref-type="fig"}A. Blood types B and O in this independent cohort also showed a higher survival than blood types A and AB. Therefore, we divided the whole group of patients into two subgroups. The subgroup analysis indicated that patients of blood group B and O also had a longer OS compared to those of blood group A and AB (63.7 months vs. 54.5months, P \< 0.001) as shown in Figure [2](#F2){ref-type="fig"}B, similar to the results showed in our hospital.

Furthermore, this independent cohort analysis date also showed that the poorly differentiated histology (P=0.005), lymphatic/vascular invasion (P=0.003), advanced pT stages (P =0.042), advanced pN stages (P=0.006), advanced tumor stages (P =0.003), ABO blood type (P=0.006) ,lower tumor height (P=0.012), bigger tumor size (P=0.019), serum CA-199 elevation (P=0.038) and serum CA-125 elevation (P=0.023) were all significantly associated with shorter survival. Meanwhile, the significant parameters in univariate analysis were further analyzed in multivariate analyses. Our results showed that the ABO blood groups were independent predictors for OS (group A: hazard ratio \[HR\] = 0.832, 95% confidence interval \[CI\] = 0.416-1.666; group B: hazard ratio \[HR\] = 0.368, 95% confidence interval \[CI\] = 0.165-0.823; group O: hazard ratio \[HR\] = 0.299, 95% confidence interval \[CI\] = 0.128-0.699; group AB: hazard ratio \[HR\] = 1, 95% confidence interval \[CI\] = Reference). Our results also revealed that lower tumor height (P=0.004), poorly differentiated histology (P=0.002), lymphatic/vascular invasion (P=0.021), advanced pT stages (P =0.012), advanced pN stages (P=0.023), advanced tumor stages (P =0.015), ABO blood type (P=0.008) and serum CA-125 elevation (P=0.031) were independent, significant predictors for OS (Table [4](#T4){ref-type="table"}). From this independent cohort, we got the similar conclusion, which further confirmed the ABO blood group is associated with survival in Chinese patients with rectal cancer and the blood type B and O were favourable prognostic factors for patients with rectal cancer.

Discussion
==========

In the present study, we investigated the value of ABO blood group in predicting the prognosis of patients who underwent radical surgery for rectal cancer. We observed significantly better survival for participants with blood group B and O compared with A and AB blood group participants. Using multivariate analysis, significant associations with rectal cancer survival were found BMI, tumor location, poorly differentiated histology, lymphatic/vascular invasion, advanced pN stages, CA125, CA19-9. Our study is the first study that investigated this relationship in a Chinese population in Northwest China region and we found that blood type is an independent factor affecting the prognosis of patients with rectal cancer.

The ABO blood group is by far the most important among human blood group systems [@B16]. The ABO blood group system is based on expression of two antigens, A and/or B on the surface of the red blood cell; because expression of these antigens is codominant, patients may have type A, type B or type AB expression patterns. Lack of expression of either antigen results in the O phenotype [@B17]. For several decades, a role for ABO blood group antigens in the development of cancer has been suspected, but the results have been inconsistent. In a study conducted by Nozoe and Colleagues in 284 patients, non-O blood groups correlated with poorly differentiated grades of the tumour and AB blood group was associated with advanced stage and large tumour size, the significance of ABO blood group distribution might be associated with biological behavior of gastric adenocarcinoma patients, but no correlation was found between different ABO blood groups and overall survival [@B18]. By contrast, in another study the B/O group was found to independently correlate with unfavourable survival among patients who had ever smoked [@B11]. A large, prospective, population-based study has consistently documented an increased risk of gastric cancer in individuals with blood type A [@B19]. However, it was found not to be a prognosis factor for patients with gastric adenocarcinoma. In a recent study conducted in 1555 patients with surgically resected colon cancer, AB blood type were more likely to have a better survival than patients with non-AB blood types[@B12], but adverse consequences were found in our study. This might be caused by our small number of subjects as well as by interpopulation variation. The exact biological theories elaborating the link between ABO blood group and cancer are still insufficient. Researchers involved in blood group ABO antigens and their genes, developed by Hakomori have shown that human blood group antigens are expressed on the surface of red blood cells and other tissues, including cells of the gastrointestinal tract[@B20], broncho pulmonary, skin, urogenital epithelial and kidney[@B21]. These glycoconjugates may participate in modifying intercellular adhesion, membrane signaling, and immune surveillance, which could in turn influence tumorigenesis [@B20].

Although the mechanism for an association between blood group and rectal cancer risk is unknown, several plausible hypotheses exist. The normal ABO antigen is lost in cancer patients, and new tumor antigens are acquired. In colon carcinomas, 50% of tumors of the proximal colon demonstrated loss of antigen expression, although expression was retained in the adjacent tissues. Of note, in tumors of the distal colon, antigens, while undetectable in the adjacent tissues, were expressed in tumor cells [@B22], [@B23], thus, a structural change in the ABO antigen may occurs in rectal cancer. A likely mechanism for the alteration of ABH antigen expression in colorectal tissue is the loss or reduction of the glycosyltransferase enzymes required for the synthesis of ABH determinants [@B24]. Modified expression of blood group antigens on cancer cells may influence tumorigenesis by altering glycosyltransferase specificity [@B25] or increasing cell motility, resistance to apoptosis and immune escape [@B21]. It is therefore possible that a specific blood type may enhance disease progression or survival [@B21], [@B26]. A number of single nucleotide polymorphism studies have suggested that ABO gene may influence the systemic chronic inflammatory response that is closely related to carcinogenesis by regulating the serum levels of several circulating adhesion molecules and plasma inflammatory markers [@B27], such as tumor necrosis factor alpha [@B28], [@B29], soluble intercellular adhesion molecule (ICAM)-1 [@B30], [@B31], E-selectin [@B32], [@B33], and P-selectin [@B30]. All these adhesion molecules are important mediators of chronic inflammation and immune cell recruitment. They may, therefore, provide a biological basis for the postulated influence of ABO on cancer survival, by directly linking ABO blood group and tumour initiation and spread [@B34].

We acknowledge the limitations of our retrospective analysis. The retrospective nature of our study greatly increased the possibility that factors related to blood group influenced which cases were included in the analysis. Additional shortcoming of our analysis include the insufficient study population, the short follow-up percentage and the unavailability of detailed covariate data, which cannot allowed us to examine confounding and effect modification by several exposures of interest. Our study population was composed of all Chinese population in Northwest China region, which somewhat limits the generalizability of our results. Accordingly, the results of further investigations including more diverse populations (white/black/brown participants) from other institutes are needed to confirm our findings. In addition, even all patients had computed tomography scans of the chest and abdomen at the time of diagnosis, but not for brain, and it is possible that some patients had asymptomatic disease at the time of primary treatment. However, this would have had a negative influence on survival. Furthermore, hospital-based control populations may not be representative of the blood group distribution in the general population if the conditions leading to hospitalization are associated with blood group.

This study was supported by grants from the Natural Science Foundation of China (No. 81472699, and No. 81272344).
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###### 

Characteristics according to ABO blood type

  Patient characteristics           Total      ABO       P-values                       
  --------------------------------- ---------- --------- ---------- --------- --------- -------
  **Total**                         **1613**   **411**   **502**    **545**   **155**   
  **Gender**                                                                            0.495
  Male                              884        237       265        295       87        
  Female                            729        174       237        250       68        
  **Age ^b^(years)**                                                                    0.466
  \<60                              807        225       250        266       66        
  ≥60                               806        186       252        279       89        
  **BMI^b^, kgm^2^**                                                                    0.231
  \<18.5                            134        39        41         46        8         
  18.5-23.9                         878        227       284        291       76        
  ≥24                               601        145       177        208       71        
  **Location^c^**                                                                       0.970
  tumour height \>12 cm             91         22        29         30        10        
  tumour height 6-12 cm             667        174       201        224       68        
  tumour height \<6 cm              855        215       272        291       77        
  **Pathology(adenocarcinoma)**                                                         0.539
  Well differentiated               220        59        64         78        19        
  Moderately differentiated         1200       292       383        406       119       
  Poorly differentiated             193        60        55         61        17        
  **Lymphatic/vascular invasion**                                                       0.785
  Yes                               547        139       168        192       48        
  No                                1066       272       334        353       107       
  **PNI**                                                                               0.836
  Yes                               1013       261       307        347       98        
  No                                600        150       195        198       57        
  **pT status**                                                                         0.027
  pT1                               165        36        42         65        22        
  pT2                               405        92        120        160       33        
  pT3                               962        260       316        292       94        
  pT4                               81         23        23         28        6         
  **pN status**                                                                         0.057
  pN0                               829        198       259        295       77        
  pN1                               517        141       171        148       57        
  pN2                               267        72        72         102       21        
  **pTNM stage**                                                                        0.043
  Stage I                           439        102       122        174       41        
  Stage II                          427        104       152        130       41        
  Stage III                         747        205       228        241       73        
  **Smoking history**                                                                   0.618
  Yes                               461        112       138        167       44        
  No                                1152       299       364        378       111       
  **Drinking history**                                                                  0.222
  Yes                               331        80        91         125       35        
  No                                1282       331       411        420       120       
  **Tumor size**                               A         B          O         AB        0.253
  ≥3.4                                         272       315        326       96        
  \<3.4                                        139       187        219       59        
  **CEA**                                                                               0.875
  Normal                            1098       281       347        364       106       
  Elevated                          515        130       155        181       49        
  **CA199**                                                                             0.231
  Normal                            1461       363       457        496       145       
  Elevated                          152        48        45         49        10        
  **CA125**                                                                             0.880
  Normal                            1561       396       485        530       150       
  Elevated                          52         15        17         15        5         

Abbreviations: BMI=body mass index; pN status=pathological node status; pT statue=pathological tumour status; pTNM status=pathological tumour-node-metastasis stage.

a: χ^2^ test (A blood type vs B blood type vs O blood type vs AB blood type).

b: Chinese definition.

c: NCOTARGET. 2015;6(34):36884-9.

###### 

Univariate and multivariate Cox regression analysis for overall survival in patients with rectal cancer

  Characteristics                   Univariate analysis   Multivariate analysis                                   
  --------------------------------- --------------------- ----------------------- --------- ------- ------------- ---------
  **Gender**                                                                      0.188                           ---
  Male                              1.00                  Reference                         ---     ---           
  Female                            0.819                 0.609-1.102                       ---     ---           
  **Age^b^ (years)**                                                              0.472                           ---
  \<60                              1.111                 0.833-1.482                       ---     ---           
  ≥60                               1                     Reference                         ---     ---           
  **BMI^b^, kgm^2^**                                                              0.007                           0.031
  \<18.5                            2.168                 1.369-3.432                       1.808   1.127-2.899   
  18.5-23.9                         1.197                 0.864-1.657                       1.045   0.751-1.454   
  ≥24                               1                     Reference                         1       Reference     
  **Location^c^**                                                                 0.050                           0.021
  tumor height \>12 cm              0.888                 0.465-1.695                       0.826   0.429-1.594   
  tumor height 6-12 cm              0.685                 0.504-0.932                       0.639   0.465-0.877   
  tumor height \<6 cm               1                     Reference                         1       Reference     
  **Pathology (adenocarcinoma)**                                                  \<0.001                         0.005
  Well differentiated               0.265                 0.161-0.437                       0.544   0.315-0.940   
  Moderately differentiated         0.346                 0.243-0.492                       0.537   0.369-0.782   
  Poorly differentiated             1                     Reference                         1       Reference     
  **lymphatic/vascular invasion**                                                 \<0.001                         0.017
  Yes                               1                     Reference                         1       Reference     
  No                                0.399                 0.299-0.534                       0.656   0.464-0.927   
  **PNI**                                                                         0.387                           ---
  Yes                               1                     Reference                         ---     ---           
  No                                0.879                 0.655-1.179                       ---     ---           
  **pT status**                                                                   \<0.001                         0.092
  pT1                               0.196                 0.085-0.452                       0.380   0.25-1.159    
  pT2                               0.252                 0.137-0.465                       0.394   0.174-0.893   
  pT3                               0.662                 0.405-1.083                       0.927   0.551-1.561   
  pT4                               1                     Reference                         1       Reference     
  **pN status**                                                                   \<0.001                         0.029
  pN0                               1.00                  Reference                         1.00    Reference     
  pN1                               2.093                 1.468-2.985                       0.369   0.125-1.087   
  pN2                               4.502                 3.138-6.458                       0.628   0.432-0.914   
  **pTNM stage**                                                                  \<0.001                         0.651
  Stage I                           0.253                 0.162-0.395                       1.624   0.463-5.703   
  Stage II                          0.441                 0.306-.0637                       1.112   0.385-3.216   
  Stage III                         1.00                  Reference                         1.00    Reference     
  **Smoking history**                                                             0.930                           ---
  Yes                               1.014                 0.739-1.392                       ---     ---           ---
  No                                1.00                  Reference                         ---     ---           
  **Drinking history**                                                            0.479                           ---
  Yes                               1.134                 0.804-1.600                       ---     ---           
  No                                1.00                  Reference                         ---     ---           
  **ABO blood type**                                                              0.010                           0.013
  A                                 1.263                 0.776-2.054                       1.186   0.720-1.954   
  B                                 0.773                 0.471-1.269                       0.709   0.429-1.172   
  O                                 0.696                 0.420-1.152                       0.689   0.412-1.152   
  AB                                1                     Reference                         1       Reference     
  **Tumor size(cm)**                                                              \<0.001   ---     ---           0.060
  \<3.4                             0.525                 0.377-0.731                       0.714   0.503-1.014   
  ≥3.4                              1                     Reference                         1       Reference     
  **Serum CEA**                                                                   0.011                           0.509
  Normal                            0.680                 0.508-0.912                       0.902   0.902-0.663   
  Elevated                          1                     Reference                         1       Reference     
  **CA19-9**                                                                      \<0.001                         0.022
  Normal                            0.408                 0.283-0.590                       0.631   0.426-0.934   
  Elevated                          1                     Reference                         1       Reference     
  **CA125**                                                                       \<0.001                         \<0.001
  Normal                            0.299                 0.184-0.486                       0.287   0.174-0.474   
  Elevated                          1                     Reference                         1       Reference     

Abbreviations: BMI=body mass index; 95% CI=95% confidence interval; HR=hazard ratio; pTNM stage=pathological tumour-node-metastasis stage.

a: Cox proportional hazards model.

b: Chinese definition.

c: NCOTARGET. 2015;6(34):36884-9.

###### 

Characteristics according to ABO blood type

  Patient characteristics           Total     ABO       P-values                      
  --------------------------------- --------- --------- ---------- --------- -------- -------
  **Total**                         **505**   **140**   **142**    **161**   **62**   
  **Gender**                                                                          0.770
  Male                              287       82        83         86        36       
  Female                            218       58        59         75        26       
  **Age ^b^(years)**                                                                  0.054
  \<60                              233       71        59         82        21       
  ≥60                               272       69        83         79        41       
  **BMI^b^, kgm^2^**                                                                  0.721
  \<18.5                            36        9         13         10        4        
  18.5-23.9                         282       83        81         87        31       
  ≥24                               187       48        48         64        27       
  **Location^c^**                                                                     0.339
  tumour height \>12 cm             30        4         7          15        4        
  tumour height 6-12 cm             209       62        62         60        25       
  tumour height \<6 cm              266       74        73         86        33       
  **Pathology(adenocarcinoma)**                                                       0.526
  Well differentiated               72        18        17         28        9        
  Moderately differentiated         376       105       113        115       43       
  Poorly differentiated             57        17        12         18        10       
  **Lymphatic/vascular invasion**                                                     0.868
  Yes                               323       88        90         107       38       
  No                                182       52        52         54        24       
  **PNI**                                                                             0.723
  Yes                               169       51        49         49        20       
  No                                336       89        93         112       42       
  **pT status**                                                                       0.024
  pT1                               60        15        12         25        8        
  pT2                               119       29        34         50        6        
  pT3                               289       85        86         74        44       
  pT4                               37        11        10         12        4        
  **pN status**                                                                       0.277
  pN0                               247       61        70         91        25       
  pN1                               171       54        47         45        25       
  pN2                               87        25        25         25        12       
  **pTNM stage**                                                                      0.038
  Stage I                           141       36        37         58        10       
  Stage II                          124       29        41         37        17       
  Stage III                         240       75        64         66        35       
  **Smoking history**                                                                 0.390
  Yes                               359       101       107        107       44       
  No                                146       39        35         54        18       
  **Drinking history**                                                                0.281
  Yes                               400       114       118        122       46       
  No                                105       26        24         39        16       
  **Tumor size**                                                                      0.155
  ≥3.4                              194       49        48         73        24       
  \<3.4                             311       91        94         88        38       
  **CEA**                                                                             0.117
  Normal                            333       90        105        99        39       
  Elevated                          172       50        37         62        23       
  **CA199**                                                                           0.889
  Normal                            469       129       132        149       59       
  Elevated                          36        11        10         12        3        
  **CA125**                                                                           0.858
  Normal                            488       134       137        157       60       
  Elevated                          17        6         5          4         2        

Abbreviations: BMI=body mass index; pN status=pathological node status; pT statue=pathological tumour status; pTNM status=pathological tumour-node-metastasis stage.

a:χ2 test (A blood type vs B blood type vs O blood type vs AB blood type).

b: Chinese definition.

c: NCOTARGET. 2015;6(34):36884-9.

###### 

Univariate and multivariate Cox regression analysis for overall survival in patients with colon cancer

  Characteristics                   Univariate analysis   Multivariate analysis                                      
  --------------------------------- --------------------- ----------------------- --------- --------- -------------- -------
  **Gender**                                                                      0.522                              ---
  Male                              1.00                  Reference                         ---       ---            
  Female                            0.29                  0.468-1.470                       ---       ---            
  **Age^b^ (years)**                                                              0.929                              ---
  \<60                              1                     Reference                         ---       ---            
  ≥60                               0.929                 0.600-1.751                       ---       ---            
  **BMI^b^, kgm^2^**                                                              0.971                              ---
  \<18.5                            1                     Reference                         ---       ---            
  18.5-23.9                         0.916                 0.312-2.690                       ---       ---            
  ≥24                               0.937                 0.531-1.653                       ---       ---            
  **Location^c^**                                                                 0.012                              0.004
  tumor height \>12 cm              1                     Reference                         1         Reference      
  tumor height 6-12 cm              1.081                 0.209-3.721                       1.080     0.595-1.961    
  tumor height \<6 cm               1.176                 0.6812.031                        1.126     0.236-5.365    
  **Pathology (adenocarcinoma)**                                                  0.005                              0.002
  Well differentiated               1                     Reference                         1         Reference      
  Moderately differentiated         1.144                 0.295-4.436                       2.338     0.539-10.135   
  Poorly differentiated             1.879                 0.583-6.054                       3.647     0.332-1.260    
  **lymphatic/vascular invasion**                                                 0.003                              0.021
  Yes                               1                     Reference                         1         Reference      
  No                                0.441                 0.257-0.758                       0.647     0.3324-1.260   
  **PNI**                                                                         0.522                              ---
  Yes                               1                     Reference                         ---       ---            
  No                                0.831                 0.473-1.462                       ---       ---            
  **pT status**                                                                   0.042                              0.012
  pT1                               0.389                 0.114-1.329                       0.158     0.015-1.617    
  pT2                               0.282                 0.095-0.841                       0.111     0.015-0.834    
  pT3                               0.759                 0.038-1.702                       0.840     0.340-2.076    
  pT4                               1                     Reference                         1         Reference      
  **pN status**                                                                   0.006                              0.023
  pN0                               0.322                 0.161-0.646                       1.00      Reference      
  pN1                               0.605                 0.313-1.168                       0.523     0.240-1.141    
  pN2                               1.00                  Reference                         0.889     0.263-1.914    
  **pTNM stage**                                                                  0.003                              0.015
  Stage I                           0.373                 0.180-0.773                       0.735     0.352-0.916    
  Stage II                          0.373                 0.174-0.801                       0.816     0.485-2.572    
  Stage III                         1.00                  Reference                         1.00      Reference      
  **Smoking history**                                                             0.069                              ---
  Yes                               1.852                 0.954-3.596                       ---       ---            ---
  No                                1.00                  Reference                         ---       ---            
  **Drinking history**                                                            0\. 112                            ---
  Yes                               3.738                 1.347-10.370                      ---       ---            
  No                                1.00                  Reference                         ---       ---            
  **ABO blood type**                                                              0.006                              0.008
  A                                 0.832                 0.416-1.666                       0.760     0.365-1.582    
  B                                 0.368                 0.165-0.823                       0.356     0.155-0.819    
  O                                 0.299                 0.128-0.699                       0.282     0.114-0.694    
  AB                                1                     Reference                         1         Reference      
  **Tumor size(cm)**                                                              0.019     ---       ---            0.241
  \<3.4                             0.622                 0.342-1.130                       0\. 673   0.343-1.323    
  ≥3.4                              1                     Reference                         1         Reference      
  **Serum CEA**                                                                   0.196                              ---
  Normal                            0.701                 0.409-1.201                       ---       ---            
  Elevated                          1                     Reference                         ---       ---            
  **CA19-9**                                                                      0.038                              0.956
  Normal                            0.854                 0.340-2.149                       0.434     0.226-1.154    
  Elevated                          1                     Reference                         1         Reference      
  CA125                                                                           0.023                              0.031
  Normal                            0\. 475               0.161-0.809                       0.854     0.199-3.668    
  Elevated                          1                     Reference                         1         Reference      

Abbreviations: BMI=body mass index; 95% CI=95% confidence interval; HR=hazard ratio; pTNM stage=pathological tumour-node-metastasis stage.

a:Cox proportional hazards model.

b:Chinese definition.

c: NCOTARGET. 2015;6(34):36884-9.
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